FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914189894> ?p ?o ?g. }

• W2914189894 endingPage "91" @default.
• W2914189894 startingPage "84" @default.
• W2914189894 abstract "Background We conducted a multicenter phase I/II trial of olaparib plus eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer (TNBC) to determine the recommended phase II dose (RP2D) (phase I) and to examine the efficacy and safety (phase II) (UMIN00009498) of the combined therapy. Patients and methods In phase I, olaparib tablet was orally administered twice daily from level 1:25 mg BID to level 7:300 mg BID, with 1.4 mg/m2 of eribulin on days 1 and 8. In phase II, patients were treated with RP2D to assess the response rate (independent review). The planned sample size was 24 with a threshold of 10%. Results One of the 24 patients enrolled in phase I experienced dose-limiting toxicity. The RP2D was established as 300 mg twice daily for olaparib and 1.4 mg/m2 for eribulin. Among the 24 patients in phase II, the median number of administered courses was 5.5 (range: 1–28). Grade ≥III adverse events included neutropenia (83.3%), leucopenia (83.3%), anaemia (41.7%), febrile neutropenia (33.3%) and thrombosis (8.3%). The response rate was 29.2% (independent; N = 7/24; 90% confidence interval [CI]; 14.6–47.9). Median progression-free survival and overall survival were 4.2 (95% CI, 3.0–7.4) and 14.5 (95% CI, 4.8–22.0) months, respectively. Germline BRCA1/2 mutation status was observed in three patients in phase I and 2 patients in phase II, respectively. The Cmax and area under the curve for olaparib increased in a dose-dependent manner, and these parameters for eribulin and olaparib were not influenced by each other. Conclusions Combination therapy of olaparib with eribulin shows antitumour activity against advanced or metastatic TNBC, but caution must be exercised in the presence of febrile neutropenia." @default.
• W2914189894 created "2019-02-21" @default.
• W2914189894 creator A5008946028 @default.
• W2914189894 creator A5012441434 @default.
• W2914189894 creator A5017930409 @default.
• W2914189894 creator A5021522674 @default.
• W2914189894 creator A5027659079 @default.
• W2914189894 creator A5039879533 @default.
• W2914189894 creator A5057200745 @default.
• W2914189894 creator A5060510665 @default.
• W2914189894 creator A5064272098 @default.
• W2914189894 creator A5067189124 @default.
• W2914189894 creator A5069272944 @default.
• W2914189894 creator A5070884525 @default.
• W2914189894 creator A5072292164 @default.
• W2914189894 creator A5075849177 @default.
• W2914189894 creator A5079777926 @default.
• W2914189894 creator A5081166185 @default.
• W2914189894 creator A5087402935 @default.
• W2914189894 creator A5089877327 @default.
• W2914189894 date "2019-03-01" @default.
• W2914189894 modified "2023-09-30" @default.
• W2914189894 title "A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes" @default.
• W2914189894 cites W1523531555 @default.
• W2914189894 cites W1969330686 @default.
• W2914189894 cites W1984087886 @default.
• W2914189894 cites W1994125700 @default.
• W2914189894 cites W1994432408 @default.
• W2914189894 cites W2025616449 @default.
• W2914189894 cites W2034154820 @default.
• W2914189894 cites W2039135884 @default.
• W2914189894 cites W2059272061 @default.
• W2914189894 cites W2064695479 @default.
• W2914189894 cites W2096843793 @default.
• W2914189894 cites W2101519297 @default.
• W2914189894 cites W2111437716 @default.
• W2914189894 cites W2117964602 @default.
• W2914189894 cites W2127152525 @default.
• W2914189894 cites W2132049943 @default.
• W2914189894 cites W2137545466 @default.
• W2914189894 cites W2166702788 @default.
• W2914189894 cites W2367214440 @default.
• W2914189894 cites W2387959609 @default.
• W2914189894 cites W2461919318 @default.
• W2914189894 cites W2602796293 @default.
• W2914189894 cites W2610368132 @default.
• W2914189894 cites W2621271973 @default.
• W2914189894 cites W2767110284 @default.
• W2914189894 cites W2891045304 @default.
• W2914189894 doi "https://doi.org/10.1016/j.ejca.2018.11.014" @default.
• W2914189894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30703739" @default.
• W2914189894 hasPublicationYear "2019" @default.
• W2914189894 type Work @default.
• W2914189894 sameAs 2914189894 @default.
• W2914189894 citedByCount "17" @default.
• W2914189894 countsByYear W29141898942019 @default.
• W2914189894 countsByYear W29141898942020 @default.
• W2914189894 countsByYear W29141898942021 @default.
• W2914189894 countsByYear W29141898942022 @default.
• W2914189894 countsByYear W29141898942023 @default.
• W2914189894 crossrefType "journal-article" @default.
• W2914189894 hasAuthorship W2914189894A5008946028 @default.
• W2914189894 hasAuthorship W2914189894A5012441434 @default.
• W2914189894 hasAuthorship W2914189894A5017930409 @default.
• W2914189894 hasAuthorship W2914189894A5021522674 @default.
• W2914189894 hasAuthorship W2914189894A5027659079 @default.
• W2914189894 hasAuthorship W2914189894A5039879533 @default.
• W2914189894 hasAuthorship W2914189894A5057200745 @default.
• W2914189894 hasAuthorship W2914189894A5060510665 @default.
• W2914189894 hasAuthorship W2914189894A5064272098 @default.
• W2914189894 hasAuthorship W2914189894A5067189124 @default.
• W2914189894 hasAuthorship W2914189894A5069272944 @default.
• W2914189894 hasAuthorship W2914189894A5070884525 @default.
• W2914189894 hasAuthorship W2914189894A5072292164 @default.
• W2914189894 hasAuthorship W2914189894A5075849177 @default.
• W2914189894 hasAuthorship W2914189894A5079777926 @default.
• W2914189894 hasAuthorship W2914189894A5081166185 @default.
• W2914189894 hasAuthorship W2914189894A5087402935 @default.
• W2914189894 hasAuthorship W2914189894A5089877327 @default.
• W2914189894 hasConcept C104317684 @default.
• W2914189894 hasConcept C121608353 @default.
• W2914189894 hasConcept C126322002 @default.
• W2914189894 hasConcept C143998085 @default.
• W2914189894 hasConcept C182979987 @default.
• W2914189894 hasConcept C185592680 @default.
• W2914189894 hasConcept C197934379 @default.
• W2914189894 hasConcept C2775930923 @default.
• W2914189894 hasConcept C2776387010 @default.
• W2914189894 hasConcept C2776694085 @default.
• W2914189894 hasConcept C2777063308 @default.
• W2914189894 hasConcept C2778375690 @default.
• W2914189894 hasConcept C2778850193 @default.
• W2914189894 hasConcept C2779962180 @default.
• W2914189894 hasConcept C2781413609 @default.
• W2914189894 hasConcept C31760486 @default.
• W2914189894 hasConcept C530470458 @default.
• W2914189894 hasConcept C55493867 @default.
• W2914189894 hasConcept C71924100 @default.

• next